OBJECTIVES The purpose of this study was to provide insight into the potential for left atrium (LA) to aortic mechanical circulatory support as a treatment for patients with heart failure with preserved ejection fraction (HFpEF).
Left ventricular assist devices (VADs) have now been tested widely in end-stage HFrEF patients for bridge to transplant, bridge to decision, destination therapy, and bridge to recovery (4) (5) (6) . However, there has been only limited experience with VADs in HFpEF (7) (8) (9) (10) (11) (12) . Some authors have even listed certain forms of HFpEF (e.g., hypertrophic cardiomyopathy [HCM]) as a contraindication for VAD therapy (13) . The specific concern stems from the smaller left ventricular (LV) chamber sizes characteristic of HFpEF that can lead to obstruction of flow into the LV inflow cannula (7) .
More recently, a micropump-based form of circulatory support has been introduced in which pump inflow is derived from the left atrium (LA), actively decompressing the LA and pulmonary circulation while improving systemic blood flow (The Synergy System, HeartWare International, Framingham, Massachusetts) (14) . These features are particularly relevant for the HFpEF population, because a common feature of all forms of HFpEF is an enlarged LA.
Other novel features of this micropump are that it is designed to be implanted in a subcutaneous pacemaker-like pocket (outside of the thorax), outflow is delivered to the subclavian artery, and the implant is via a minimally-invasive procedure. The pump is designed to provide partial mechanical support (2 to 4 l/min) and reduce LA pressure, and for HFrEF patients, the system is intended The purpose of this study is to elucidate the theoretical hemodynamic effects of the Synergy System in patients with different forms of HFpEF using a previously-described cardiovascular simulation (16, 17) that successfully predicted hemodynamic effects of Synergy use in HFrEF (14) . Clinical considerations regarding when device implantation might be considered appropriate for an HFpEF patient are also discussed.
METHODS

HFpEF PHENOTYPES AND BASELINE HEMODYNAMICS.
Four categories of HFpEF are listed in Table 1 . Corresponding representative hemodynamic profiles are shown in Table 2 . Type 1 HFpEF includes patients with HCM on the basis of inherited genetic mutation.
Representative hemodynamics for this group were obtained from the subset of HCM patients reported by Kato et al. (18) who underwent heart transplant for intractable symptoms and had an LV ejection fraction (EF) $50%. Type 2 HFpEF includes patients with restrictive forms of cardiomyopathy, such as infiltrative diseases and endomyocardial fibrosis. One of the more common forms of type 2 HFpEF is amyloid cardiomyopathy. Representative hemodynamics for device. With the simulation set for Synergy inflow sourcing from the LV, the Synergy pump was ramped from 20,000 to 28,000 rpm (the maximum rate), which yielded a maximum flow rate of w4 l/min, similar to or slightly less than flow rates reported to be used in RCM and HCM patients with full support VADs (e.g., HVAD [HeartWare]) (7).
The simulation was then set to source blood from the LA, and rpms were ramped over the same range.
The hemodynamic parameters included aortic and pulmonary arterial pressures, central venous pressure, pulmonary capillary wedge pressures (PCWPs), and total cardiac output (CO), which was the sum of flow from the LV and from the device.
RESULTS
The simulated hemodynamic effect of the MCS by Synergy viewed through the window of LV and LA pressure-volume relationships and loops in the prototypical patient with HCM is illustrated in Figure 1 .
At baseline (without MCS), HCM ventricular volumes are lower than normal both at end-diastole and endsystole, pressure generation is low-normal, and enddiastolic pressure is higher than normal ( Figures 1A   and 1C , pressure-volume loops in black). Note the end-diastolic volume of w75 ml, compared with a normal value that would range between 100 to 150 ml.
With Synergy inflow from the LV ( Figures 1A and 1B) , EFFECT ON CARDIAC OUTPUT. With the partial MCS that the Synergy pump intends to provide, the total cardiac output is shared between the pump and the heart. As the speed of the pump is increased, pump flow increases and the intrinsic cardiac output decreases, as is evident from the pressure-volume loops of Figure 1C , which become progressively more narrow (i.e., decreased stroke volume) as rpms are increased.
The effect of Synergy support at a speed of 28,000 rpm on intrinsic and overall cardiac output is summarized in Figures 3A to 3C . For these parameters, the effect of MCS is similar with LV or LA cannulation. There is slightly greater LV unloading with inflow from the LV, but pump flow and total CO were similar with the 2 approaches. Note that for HFpEF-HTN, baseline CO was within the normal range and increased to a supernormal range with MCS.
EFFECT ON AORTIC AND PULMONARY PRESSURES.
The effect of MCS on other hemodynamic parameters is summarized in Figures 3D to 3F . There are significant decreases in pulmonary capillary wedge pressure that result in decreased pulmonary artery systolic pressure (despite the increase in CO), which are comparable for pump inflow from the LV and the LA. These trends were similar for pulmonary diastolic and mean pressures (data not shown). Aortic systolic pressure increased with MCS, but the increase was greater when the inflow was from the LA than from the LV. These trends were similar for aortic diastolic and mean pressures (data not shown). All of these trends depended on pump speed. Figure 1 .
Burkhoff et al. Table 2 ). These hemodynamic abnormalities can all be traced back to LV diastolic dysfunction, and result in signs and symptoms classically associated with diastolic heart failure. However, application of traditional MCS systems is difficult in these patients because of the small LV chamber size.
Topilsky et al. (7) Although there is a predicted, substantial beneficial effect of MCS on PCWP, the potential effect of a further increase in blood pressure needs to be considered in these patients, especially in the setting of anticoagulation and antiplatelet therapies required for pump-based devices. In addition, the high pressure head against which the device would have to pump could, in extreme cases, limit its hemodynamic effectiveness. For these reasons, it is prudent that such patients be considered for MCS on a caseby-case basis. An additional consideration is that although, on average, resting cardiac output is essentially normal in type 4 HFpEF patients ( Table 2) , it is known that these patients have a significant limitation of cardiac output at peak exercise (27, 28) .
Thus, the effect of MCS on cardiac output might prove beneficial during exertion.
One final factor to consider is the varying degrees 
